Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050814 | 0.85 | CCR8 (0.46) | CCR8KMT2AHSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL29974781 | 0.85 | CCR8 (0.46) | CCR8KMT2AHSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL1886773 | 0.84 | CCR8 (0.52) | CCR8KMT2AHSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL30950714 | 0.74 | GPR84 (0.45) | TNFRIPK1 | |
| SCHEMBL16647184 | 0.72 | MEN1 (0.36) | KMT2AALDH1A1 | |
| SCHEMBL9529665 | 0.71 | CCR8 (0.39) | CCR8KMT2AHSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL15579270 | 0.70 | ALDH1A1 (0.49) | CCR8KMT2AHSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL19370124 | 0.69 | CCR8 (0.52) | CCR8KMT2AHSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL21050763 | 0.69 | CCR8 (0.47) | CCR8KMT2AHSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL18305761 | 0.68 | TNF (0.34) | CCR8KMT2ATNFRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | CCR8 2420/4885KMT2A 1959/4885HSD17B10 599/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | CCR8 2420/4885KMT2A 1959/4885HSD17B10 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.